Literature DB >> 6734691

Haemodynamic effects of intravenous cibenzoline in patients with coronary heart disease.

M van den Brand, P Serruys, Y de Roon, M F Aymard, A Dufour.   

Abstract

The effect of a single dose of cibenzoline ( (diphenyl 2,2 cyclopropyl)--2 imidazoline, Cipralan ), a new compound with antiarrhythmic properties was studied in 14 patients undergoing routine heart catheterization for suspected coronary artery disease. The effect of the drug on dP/dt, Vmax TP, Vce, negative dP/dt, heart rate (HR), left ventricular systolic pressure (LVSP), left ventricular end-diastolic pressure (LVEDP), cardiac index (CI) and systemic vascular resistance (SVR) was measured before and after drug administration. A significant decrease in left ventricular isometric contraction parameters was manifested immediately after injection, with its maximal effect 2 to 5 min after injection. An increase in HR, a decrease in LVSP, a decrease in CI and an increase in SVR were observed; LVEDP was not significantly altered, nor was negative dP/dt. The effect of the drug on Vmax TP and LVEDP was also examined during two atrial pacing stress tests ( APST ) done before and 10 to 20 min after drug administration. Although the negative inotropic action of the drug was apparent during the second APST , the effect was less pronounced at higher paced heart rates. No difference in the two tests was found between the maximal paced heart rate, nor was there a difference in the angina threshold. Finally the plasma level of the drug and the changes in certain parameters were compared. A positive correlation was found between the plasma level and dP/dt, Vmax TP and cardiac index.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6734691     DOI: 10.1007/BF00548758

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  7 in total

1.  Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1976-10

2.  A computer system for real time analysis of cardiac catheterization data.

Authors:  G T Meester; N Bernard; C Zeelenberg; R W Brower; P G Hugenholtz
Journal:  Cathet Cardiovasc Diagn       Date:  1975

3.  Cardiovascular and antiarrhythmic effects of aprindine (AC1802) during partial occlusion of a coronary artery in the pig.

Authors:  P D Verdouw; W J Remme; P G Hugenholtz
Journal:  Cardiovasc Res       Date:  1977-07       Impact factor: 10.787

4.  [Pharmacokinetic study of a new antiarrhythmic drug, cibenzoline, during the acute phase of myocardial infarction. Therapeutic correlations].

Authors:  P Desoutter; A Dufour; M F Aymard; R Haiat
Journal:  Therapie       Date:  1983 May-Jun       Impact factor: 2.070

5.  Antiarrhythmic and hemodynamic actions of flecainide acetate (R-818) in the ischemic porcine heart.

Authors:  P D Verdouw; J W Deckers; G J Conrad
Journal:  J Cardiovasc Pharmacol       Date:  1979 Jul-Aug       Impact factor: 3.105

6.  Effects on rabbit nodal, atrial, ventricular and Purkinje cell potentials of a new antiarrhythmic drug, cibenzoline, which protects against action potential shortening in hypoxia.

Authors:  J S Millar; E M Vaughan Williams
Journal:  Br J Pharmacol       Date:  1982-03       Impact factor: 8.739

7.  Pharmacokinetics in man of a new antiarrhythmic drug, cibenzoline.

Authors:  M Canal; B Flouvat; D Tremblay; A Dufour
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

  7 in total
  5 in total

1.  Effect of food on cibenzoline bioavailability.

Authors:  J W Massarella; H P Blumenthal; T Silvestri; A Lin
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 2.  Cibenzoline. A review of its pharmacological properties and therapeutic potential in arrhythmias.

Authors:  D W Harron; R N Brogden; D Faulds; A Fitton
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

3.  Effects of the Na+ antagonist cibenzoline on left ventricular function of postischemic hearts.

Authors:  H M Hoffmeister; M E Beyer; L Seipel
Journal:  Cardiovasc Drugs Ther       Date:  1995-04       Impact factor: 3.727

4.  Inhibition of the myocardial Ca2+ inward current by the class 1 antiarrhythmic agent, cibenzoline.

Authors:  M Holck; W Osterrieder
Journal:  Br J Pharmacol       Date:  1986-04       Impact factor: 8.739

5.  Effects of cibenzoline, a new class Ia antiarrhythmic drug, on various membrane ionic currents and action potentials of guinea-pig ventricular cells.

Authors:  T Sato; B Wu; T Kiyosue; M Arita
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-08       Impact factor: 3.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.